Publications by authors named "David D L Bowtell"

Claim this Profile
P
PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis.
Stamatios Petousis, Ilker Kahramanoglu, Christian Appenzeller-Herzog, Martina A Angeles, Chrysoula Margioula-Siarkou, David D L Bowtell

JAMA Netw Open· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploiting dysregulated iron homeostasis to eradicate persistent high-grade serous ovarian cancer.
Carmelo Cerra, Madeleine R C Tancock, Niko Thio, Ada Koo, AnnRann Wong, David D L Bowtell

Cell Death Discov· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond deficiency: Clinical and molecular predictors of survival in patients with -deficient tubo-ovarian high-grade serous carcinoma.
Tibor A Zwimpfer, Sian Fereday, Ahwan Pandey, Dinuka Ariyaratne, Madawa W Jayawardana, David D L Bowtell

medRxiv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis.
Zhuxuan Fu, Lauren Borho, Sarah E Taylor, Linda E Kelemen, Anna DeFazio, David D L Bowtell

Gynecol Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming intra-tumoral heterogeneity for biomarker discovery in the high-grade serous ovarian cancer proteome.
Srikanth S Manda, Maiken M Espersen, Cristina Mapagu, Natalie Bouantoun, Jessica Boros, David D L Bowtell

NPJ Precis Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of Associations with Epidemiologic Factors by High-Grade Serous Ovarian Cancer Gene Expression Subtypes.
Lindsay J Collin, Kara L Cushing-Haugen, Kathryn L Terry, Ellen L Goode, Anna H Wu, David D L Bowtell

Cancer Epidemiol Biomarkers Prev· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exome sequencing identifies HELB as a novel susceptibility gene for non-mucinous, non-high-grade-serous epithelial ovarian cancer.
Ed M Dicks, Jonthan P Tyrer, Suzana Ezquina, Michelle Jones, John Baierl, David D L Bowtell

Eur J Hum Genet· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma.
Flurina A M Saner, Kazuaki Takahashi, Timothy Budden, Ahwan Pandey, Dinuka Ariyaratne, David D L Bowtell

Clin Cancer Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.
Ksenija Nesic, John J Krais, Yifan Wang, Cassandra J Vandenberg, Pooja Patel, David D L Bowtell

Mol Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Timing of whole genome duplication is associated with tumor-specific MHC-II depletion in serous ovarian cancer.
Nikki L Burdett, Madelynne O Willis, Ahwan Pandey, Laura Twomey, Sara Alaei, David D L Bowtell

Nat Commun· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group.
Nadja Stiegeler, Dale W Garsed, George Au-Yeung, David D L Bowtell, Viola Heinzelmann-Schwarz

Front Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities.
Nicholas W Bateman, Tamara Abulez, Anthony R Soltis, Andrew McPherson, Seongmin Choi, David D L Bowtell

NPJ Precis Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities.
Nicholas W Bateman, Tamara Abulez, Anthony R Soltis, Andrew McPherson, Seongmin Choi, David D L Bowtell

NPJ Precis Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer.
Nikki L Burdett, Madelynne O Willis, Ahwan Pandey, Sian Fereday, , David D L Bowtell

Sci Rep· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent RB1 loss and -deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma.
Flurina A M Saner, Kazuaki Takahashi, Timothy Budden, Ahwan Pandey, Dinuka Ariyaratne, David D L Bowtell

medRxiv· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.
Gwo Yaw Ho, Cassandra J Vandenberg, Ratana Lim, Elizabeth L Christie, Dale W Garsed, David D L Bowtell

Ther Adv Med Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas.
Karolin Heinze, Evan S Cairns, Shelby Thornton, Bronwyn Harris, Katy Milne, David D L Bowtell

Clin Cancer Res· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.
Ksenija Nesic, John J Krais, Cassandra J Vandenberg, Yifan Wang, Pooja Patel, David D L Bowtell

medRxiv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interferon-ε is a tumour suppressor and restricts ovarian cancer.
Zoe R C Marks, Nicole K Campbell, Niamh E Mangan, Cassandra J Vandenberg, Linden J Gearing, David D L Bowtell

Nature· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes.
Paula Cunnea, Edward W Curry, Elizabeth L Christie, Katherine Nixon, Chun Hei Kwok, David D L Bowtell

Cell Rep Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma.
Omali Pitiyarachchi, Yeh Chen Lee, Hao-Wen Sim, Sivatharsny Srirangan, Cristina Mapagu, David D L Bowtell

Transl Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Amplification as a Therapeutic Target.
George Au-Yeung, Linda Mileshkin, David D L Bowtell

J Clin Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer.
Nikki L Burdett, Madelynne O Willis, Kathryn Alsop, Allison L Hunt, Ahwan Pandey, David D L Bowtell

Nat Genet· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery.
Minh Tung Phung, Penelope M Webb, Anna DeFazio, Sian Fereday, Alice W Lee, David D L Bowtell

Gynecol Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.
Dale W Garsed, Ahwan Pandey, Sian Fereday, Catherine J Kennedy, Kazuaki Takahashi, David D L Bowtell

Nat Genet· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis